Also trades as: MLCT (OTC) · $vol 0M
VBIO NASDAQ
Valion Bio, Inc.
1W: -24.9%
1M: -53.0%
YTD: -49.1%
$0.29
+0.01 (+1.80%)
Weekly Expected Move ±17.5%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.9M
52W Range0.251-5.6
Volume148,400
Avg Volume487,446
Beta1.83
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichael R. Cavanaugh
Employees52
SectorHealthcare
IndustryBiotechnology
IPO Date2021-11-11
Websitevalionbio.com
1305 E. Houston Street
San Antonio, TX 78205
US
San Antonio, TX 78205
US
216 304 6556
About Valion Bio, Inc.
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Wolf Lisa G | M-Exempt | 92 | — | 2026-06-18 |
| Wolf Lisa G | M-Exempt | 92 | — | 2026-06-18 |
| Handley Michael K | M-Exempt | 2,206 | — | 2026-05-18 |
| Handley Michael K | M-Exempt | 2,206 | — | 2026-05-18 |
| Lackey Melinda | A-Award | 45,000 | $0.96 | 2026-05-01 |